# Tilray Brands, Inc.: financial statements, quarterly

TLRY · Nasdaq · CIK 1731348 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 31

Pages: [Overview](/companies/tlry.md) · [Financials](/companies/tlry/financials.md) · [Filings](/companies/tlry/filings.md) · [Insiders](/companies/tlry/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tlry/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [194](/filings/0001437749-25-000868.md) | [188](/filings/0001437749-25-011431.md) | [230 d](/filings/0001437749-26-024698.md) | [200](/filings/0001437749-25-030797.md) | [211](/filings/0001437749-26-000902.md) | [186](/filings/0001437749-26-010907.md) | [225 d](/filings/0001437749-26-024698.md) | [210](/filings/0001437749-26-032382.md) | [218](/filings/0001437749-26-000902.md) | [207](/filings/0001437749-26-010907.md) | [282 d](/filings/0001437749-26-024698.md) | [257](/filings/0001437749-26-032382.md) |
| Cost of revenue | $m | [146](/filings/0001437749-25-000868.md) | [139](/filings/0001437749-25-011431.md) | [148 d](/filings/0001437749-26-024698.md) | [140](/filings/0001437749-25-030797.md) | [150](/filings/0001437749-26-000902.md) | [134](/filings/0001437749-26-010907.md) | [157 d](/filings/0001437749-26-024698.md) | [152](/filings/0001437749-26-032382.md) | [160](/filings/0001437749-26-000902.md) | [152](/filings/0001437749-26-010907.md) | [191 d](/filings/0001437749-26-024698.md) | [180](/filings/0001437749-26-032382.md) |
| Gross profit | $m | [47.4](/filings/0001437749-25-000868.md) | [49.4](/filings/0001437749-25-011431.md) | [82.4 d](/filings/0001437749-26-024698.md) | [59.7](/filings/0001437749-25-030797.md) | [61.2](/filings/0001437749-26-000902.md) | [52.0](/filings/0001437749-26-010907.md) | [67.6 d](/filings/0001437749-26-024698.md) | [57.5](/filings/0001437749-26-032382.md) | [57.5](/filings/0001437749-26-000902.md) | [55.0](/filings/0001437749-26-010907.md) | [90.5 d](/filings/0001437749-26-024698.md) | [77.5](/filings/0001437749-26-032382.md) |
| Research and development | $m | [0.1](/filings/0001437749-25-000868.md) | [0.1](/filings/0001437749-25-011431.md) | [0.4 d](/filings/0001437749-26-024698.md) | [0.1](/filings/0001437749-25-030797.md) | [0.1](/filings/0001437749-26-000902.md) | [0.1](/filings/0001437749-26-010907.md) | [0.0 d](/filings/0001437749-26-024698.md) | [0.0](/filings/0001437749-26-032382.md) | [0.1](/filings/0001437749-26-000902.md) | [0.1](/filings/0001437749-26-010907.md) | [0.2 d](/filings/0001437749-26-024698.md) | [0.1](/filings/0001437749-26-032382.md) |
| Operating income | $m | [(41.8)](/filings/0001437749-25-000868.md) | [(82.1)](/filings/0001437749-25-011431.md) | [(16.5) d](/filings/0001437749-26-024698.md) | [(36.6)](/filings/0001437749-25-030797.md) | [(42.2)](/filings/0001437749-26-000902.md) | [(760)](/filings/0001437749-26-010907.md) | [(1,444) d](/filings/0001437749-26-024698.md) | [2.1](/filings/0001437749-26-032382.md) | [(22.3)](/filings/0001437749-26-000902.md) | [(26.4)](/filings/0001437749-26-010907.md) | [(16.5) d](/filings/0001437749-26-024698.md) | [(24.1)](/filings/0001437749-26-032382.md) |
| Income tax | $m | [(3.4)](/filings/0001437749-25-000868.md) | [(2.9)](/filings/0001437749-25-011431.md) | [(27.6) d](/filings/0001437749-26-024698.md) | [0.9](/filings/0001437749-25-030797.md) | [2.0](/filings/0001437749-26-000902.md) | [1.2](/filings/0001437749-26-010907.md) | [(125) d](/filings/0001437749-26-024698.md) | [(2.3)](/filings/0001437749-26-032382.md) | [3.5](/filings/0001437749-26-000902.md) | [2.0](/filings/0001437749-26-010907.md) | [13.9 d](/filings/0001437749-26-024698.md) | [1.7](/filings/0001437749-26-032382.md) |
| Net income | $m | [(49.0)](/filings/0001437749-25-000868.md) | [(92.7)](/filings/0001437749-25-011431.md) | [(31.7) d](/filings/0001437749-26-024698.md) | [(39.2)](/filings/0001437749-25-030797.md) | [(85.3)](/filings/0001437749-26-000902.md) | [(789)](/filings/0001437749-26-010907.md) | [(1,273) d](/filings/0001437749-26-024698.md) | [(0.3)](/filings/0001437749-26-032382.md) | [(44.9)](/filings/0001437749-26-000902.md) | [(26.6)](/filings/0001437749-26-010907.md) | [(49.6) d](/filings/0001437749-26-024698.md) | [(43.1)](/filings/0001437749-26-032382.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001437749-25-000868.md) | [(0.12)](/filings/0001437749-25-011431.md) | not reported | [(0.04)](/filings/0001437749-25-030797.md) | [(0.99)](/filings/0001437749-26-000902.md) | [(8.69)](/filings/0001437749-26-010907.md) | not reported | [0.00](/filings/0001437749-26-032382.md) | [(0.41)](/filings/0001437749-26-000902.md) | [(0.24)](/filings/0001437749-26-010907.md) | not reported | [(0.32)](/filings/0001437749-26-032382.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0001437749-25-000868.md) | [(0.12)](/filings/0001437749-25-011431.md) | not reported | [(0.04)](/filings/0001437749-25-030797.md) | [(0.99)](/filings/0001437749-26-000902.md) | [(8.69)](/filings/0001437749-26-010907.md) | not reported | [0.00](/filings/0001437749-26-032382.md) | [(0.41)](/filings/0001437749-26-000902.md) | [(0.24)](/filings/0001437749-26-010907.md) | not reported | [(0.32)](/filings/0001437749-26-032382.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | period not labelled (2024-12-31) | Q3 FY2025 (2025-02-28) | FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | period not labelled (2025-12-31) | Q3 FY2026 (2026-02-28) | FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [228](/filings/0001437749-25-023703.md) | [205](/filings/0001437749-24-031042.md) | [190](/filings/0001437749-25-000868.md) | [200](/filings/0001437749-25-011431.md) | not reported | [222](/filings/0001437749-26-010907.md) | [265](/filings/0001437749-25-030797.md) | [247](/filings/0001437749-26-000902.md) | [222](/filings/0001437749-26-024698.md) | [205](/filings/0001437749-26-010907.md) | [226](/filings/0001437749-26-032382.md) | [215](/filings/0001437749-26-032382.md) |
| Current assets | $m | [678](/filings/0001437749-25-023703.md) | [726](/filings/0001437749-24-031042.md) | [707](/filings/0001437749-25-000868.md) | [686](/filings/0001437749-25-011431.md) | not reported | [689](/filings/0001437749-26-010907.md) | [701](/filings/0001437749-25-030797.md) | [729](/filings/0001437749-26-000902.md) | [689](/filings/0001437749-26-024698.md) | [719](/filings/0001437749-26-010907.md) | [792](/filings/0001437749-26-032382.md) | [808](/filings/0001437749-26-032382.md) |
| Total assets | $m | [4,222](/filings/0001437749-25-023703.md) | [4,262](/filings/0001437749-24-031042.md) | [4,192](/filings/0001437749-25-000868.md) | [3,403](/filings/0001437749-25-011431.md) | not reported | [2,074](/filings/0001437749-26-010907.md) | [2,083](/filings/0001437749-25-030797.md) | [2,099](/filings/0001437749-26-000902.md) | [2,074](/filings/0001437749-26-024698.md) | [2,075](/filings/0001437749-26-010907.md) | [2,328](/filings/0001437749-26-032382.md) | [2,328](/filings/0001437749-26-032382.md) |
| Current liabilities | $m | [299](/filings/0001437749-25-023703.md) | [294](/filings/0001437749-24-031042.md) | [279](/filings/0001437749-25-000868.md) | [262](/filings/0001437749-25-011431.md) | not reported | [280](/filings/0001437749-26-010907.md) | [268](/filings/0001437749-25-030797.md) | [259](/filings/0001437749-26-000902.md) | [280](/filings/0001437749-26-024698.md) | [258](/filings/0001437749-26-010907.md) | [358](/filings/0001437749-26-032382.md) | [431](/filings/0001437749-26-032382.md) |
| Total liabilities | $m | [778](/filings/0001437749-25-023703.md) | [778](/filings/0001437749-24-031042.md) | [738](/filings/0001437749-25-000868.md) | [701](/filings/0001437749-25-011431.md) | not reported | [585](/filings/0001437749-26-010907.md) | [562](/filings/0001437749-25-030797.md) | [552](/filings/0001437749-26-000902.md) | [585](/filings/0001437749-26-024698.md) | [549](/filings/0001437749-26-010907.md) | [733](/filings/0001437749-26-032382.md) | [721](/filings/0001437749-26-032382.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [120](/filings/0001437749-26-032382.md) | [118](/filings/0001437749-26-032382.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [18.0](/filings/0001437749-25-023703.md) | [18.1](/filings/0001437749-24-031042.md) | [17.8](/filings/0001437749-25-000868.md) | [10.7](/filings/0001437749-25-011431.md) | not reported | [7.2](/filings/0001437749-26-010907.md) | [8.2](/filings/0001437749-25-030797.md) | [8.6](/filings/0001437749-26-000902.md) | [7.2](/filings/0001437749-26-024698.md) | [8.8](/filings/0001437749-26-010907.md) | [8.8](/filings/0001437749-26-032382.md) | [8.7](/filings/0001437749-26-032382.md) |
| Shareholders' equity | $m | [3,443](/filings/0001437749-25-023703.md) | [3,478](/filings/0001437749-24-031042.md) | [3,473](/filings/0001437749-25-000868.md) | [2,730](/filings/0001437749-25-011431.md) | [2,702](/filings/0001437749-26-010907.md) | [1,511](/filings/0001437749-26-010907.md) | [1,541](/filings/0001437749-25-030797.md) | [1,580](/filings/0001437749-26-000902.md) | [1,511](/filings/0001437749-26-024698.md) | [1,557](/filings/0001437749-26-010907.md) | [1,614](/filings/0001437749-26-032382.md) | [1,623](/filings/0001437749-26-032382.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q4 FY2024 (2024-05-31) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(30.4) d](/filings/0001437749-25-000868.md) | [(15.4) d](/filings/0001437749-25-011431.md) | [30.7 d](/filings/0001437749-26-024698.md) | [(35.3)](/filings/0001437749-25-030797.md) | [(40.7) d](/filings/0001437749-26-000902.md) | [(5.8) d](/filings/0001437749-26-010907.md) | [(12.8) d](/filings/0001437749-26-024698.md) | [(1.3)](/filings/0001437749-26-032382.md) | [(8.5) d](/filings/0001437749-26-000902.md) | [(21.9) d](/filings/0001437749-26-010907.md) | [(37.3) d](/filings/0001437749-26-024698.md) | [(16.5)](/filings/0001437749-26-032382.md) |
| Capital expenditure | $m | [5.9 d](/filings/0001437749-25-000868.md) | [9.5 d](/filings/0001437749-25-011431.md) | [9.7 d](/filings/0001437749-25-023703.md) | [6.7](/filings/0001437749-24-031042.md) | [5.4 d](/filings/0001437749-25-000868.md) | [14.4 d](/filings/0001437749-25-011431.md) | [6.3 d](/filings/0001437749-25-023703.md) | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q2 FY2023 (2022-11-30) | Q3 FY2023 (2023-02-28) | Q1 FY2024 (2023-08-31) | Q2 FY2024 (2023-11-30) | Q3 FY2024 (2024-02-29) | Q1 FY2025 (2024-08-31) | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [612](/filings/0001437749-24-001001.md) | [616](/filings/0001437749-24-011541.md) | [691](/filings/0001437749-24-031042.md) | [731](/filings/0001437749-25-000868.md) | [754](/filings/0001437749-25-011431.md) | [875](/filings/0001437749-25-030797.md) | [86.5](/filings/0001437749-26-000902.md) | [90.8](/filings/0001437749-26-010907.md) | [106](/filings/0001437749-26-032382.md) | [110](/filings/0001437749-26-000902.md) | [113](/filings/0001437749-26-010907.md) | [133](/filings/0001437749-26-032382.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 147,787,523 at 2026-10-06, from the cover of the [10-Q filed 2026-10-08](/filings/0001437749-26-032382.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.